Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 90

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 90
---
 entity particular opportunities or information should be presented.
If, as a result of such conflict, we are deprived of investment, business or information, the execution of our business plan and our
ability to effectively compete in the marketplace may be adversely affected.

<div align='center'>55

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus contains
forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives
and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements
of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology
such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,”
“could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,”
“objective,” “plan,” “predict,” “potential,” “positioned,” “seek,”
“should,” “target,” “will,” “would,” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking
statements include, but are not limited to, statements about:

| ● | the ability of our clinical                                                                             
 trials to demonstrate safety and efficacy of our future product candidates, and other positive results; |

| ● | the timing and focus of                                                                                      
 our future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |

| ● | the size of the market                                                                                                           
 opportunity for our future product candidates, including our estimates of the number of patients who suffer from the diseases we 
 are targeting;                                                                                                                   |

| ● | our ability to accurately                                                          
 identify demand for our Gelrin hydrogel platform or any future product candidates; |

| ● | the success of competing                    
 therapies that are or may become available; |

| ● | the beneficial characteristics,                                            
 safety, efficacy and therapeutic effects of our future product candidates; |

| ● | our ability to obtain FDA                                                                                      
 approval for our GelrinC product and obtain and maintain regulatory approval of our future product candidates; |

| ● | our ability to obtain market                                                                                                    
 acceptance of our Gelrin hydrogel platform and any future product candidates from the medical community and third-party payors; |

| ● | our plans relating to the                                                                                               
 further development of our future product candidates, including additional